Empagliflozin attenuates traumatic brain injury-induced atherosclerosis and norepinephrine-induced vascular smooth muscle cell responses

Abstract

Traumatic brain injury (TBI) is associated with increased long-term cardiovascular risk, but strategies to limit post-traumatic vascular disease are lacking. We tested whether empagliflozin, a sodium-glucose cotransporter 2 inhibitor, attenuates TBI-induced atherosclerosis in apolipoprotein E-deficient mice.

The paper